Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 588.60, up by 16.70 points or 2.92% from its previous closing of Rs. 571.90 on the BSE.

The scrip opened at Rs. 582.00 and has touched a high and low of Rs. 599.00 and Rs. 576.25 respectively. So far 56702 shares were traded on the counter.

The BSE group 'A' stock of face value Re. 1 has touched a 52 week high of Rs. 653.10 on 03-Mar-2014 and a 52 week low of Rs. 423.18 on 10-Apr-2013.

Last one week high and low of the scrip stood at Rs. 585.00 and Rs. 566.00 respectively. The current market cap of the company is Rs. 122146.89 crore.

The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.23% and 8.11% respectively.

Sun Pharmaceutical Industries has entered into definitive agreements with Ranbaxy Laboratories pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction. Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.

This exchange ratio represents an implied value of Rs 457 for each Ranbaxy share, a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy’s 60-day volume-weighted average share price, in each case, as of the close of business on April 4, 2014.

The combination of Sun Pharma and Ranbaxy will create the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India. The combined entity will have operations in 65 countries, 47 manufacturing facilities across 5 continents, and a significant platform of specialty and generic products marketed globally, including 629 ANDAs.

On a pro forma basis, the combined entity’s revenues are estimated at $4.2 billion with EBITDA of $1.2 billion for the twelve month period ended December 31, 2013. The transaction value implies a revenue multiple of 2.2 based on 12 months ended December 31, 2013.